You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameGalantamine
Accession NumberDB00674  (APRD00206, EXPT01628)
TypeSmall Molecule
GroupsApproved
Description

A benzazepine derived from norbelladine. It is found in galanthus and other amaryllidaceae. Galantamine is a cholinesterase inhibitor that has been used to reverse the muscular effects of gallamine triethiodide and tubocurarine, and has been studied as a treatment for Alzheimer’s disease and other central nervous system disorders. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
(-)-GalanthamineNot AvailableNot Available
GalanthamineNot AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Galantamine Hydrobromidetablet, film coated4 mgoralPatriot Pharmaceuticals, LLC2001-02-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantamine Hydrobromidetablet, film coated8 mgoralPatriot Pharmaceuticals, LLC2001-02-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantamine Hydrobromidetablet, film coated12 mgoralPatriot Pharmaceuticals, LLC2001-02-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantamine Hydrobromidecapsule, extended release8 mgoralPatriot Pharmaceuticals, LLC2004-12-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantamine Hydrobromidecapsule, extended release16 mgoralPatriot Pharmaceuticals, LLC2004-12-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantamine Hydrobromidecapsule, extended release24 mgoralPatriot Pharmaceuticals, LLC2004-12-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Razadynetablet, film coated8 mgoralRebel Distributors Corp2001-02-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Razadynetablet, film coated12 mgoralRebel Distributors Corp2001-02-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Razadynecapsule, extended release8 mgoralJanssen Pharmaceuticals, Inc.2004-12-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Razadynecapsule, extended release16 mgoralJanssen Pharmaceuticals, Inc.2004-12-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Razadynecapsule, extended release24 mgoralJanssen Pharmaceuticals, Inc.2004-12-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Razadynetablet, film coated4 mgoralJanssen Pharmaceuticals, Inc.2001-03-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Razadynetablet, film coated8 mgoralJanssen Pharmaceuticals, Inc.2001-03-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Razadynetablet, film coated12 mgoralJanssen Pharmaceuticals, Inc.2001-03-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Razadynesolution4 mg/mLoralJanssen Pharmaceuticals, Inc.2001-06-22Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Galantamine Hydrobromidecapsule, extended release8 mgoralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-05-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantamine Hydrobromidecapsule, extended release16 mgoralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-05-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantamine Hydrobromidecapsule, extended release24 mgoralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-05-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated4 mgoralMylan Pharmaceuticals Inc.2008-08-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated8 mgoralMylan Pharmaceuticals Inc.2008-08-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated12 mgoralMylan Pharmaceuticals Inc.2008-08-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantamine Hydrobromidecapsule, extended release8 mgoralMylan Pharmaceuticals Inc.2008-08-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantamine Hydrobromidecapsule, extended release16 mgoralMylan Pharmaceuticals Inc.2008-08-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantamine Hydrobromidecapsule, extended release24 mgoralMylan Pharmaceuticals Inc.2008-08-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated4 mgoralBarr Laboratories Inc.2008-08-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated8 mgoralBarr Laboratories Inc.2008-08-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated12 mgoralBarr Laboratories Inc.2008-08-28Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantamine Hydrobromidecapsule, extended release8 mgoralBarr Laboratories Inc.2008-10-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantamine Hydrobromidecapsule, extended release16 mgoralBarr Laboratories Inc.2008-10-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantamine Hydrobromidecapsule, extended release24 mgoralBarr Laboratories Inc.2008-10-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantamine Hydrobromidecapsule, extended release8 mgoralWatson Laboratories, Inc.2009-12-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantamine Hydrobromidecapsule, extended release16 mgoralWatson Laboratories, Inc.2009-12-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantamine Hydrobromidecapsule, extended release24 mgoralWatson Laboratories, Inc.2009-12-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated4 mgoralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-05-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated8 mgoralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-05-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated12 mgoralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-05-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantamine Hydrobromidecapsule, extended release8 mgoralSun Pharma Global FZE2011-02-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantamine Hydrobromidecapsule, extended release16 mgoralSun Pharma Global FZE2011-02-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantamine Hydrobromidecapsule, extended release24 mgoralSun Pharma Global FZE2011-02-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated4 mgoralMylan Institutional Inc.2012-08-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated8 mgoralMylan Institutional Inc.2012-08-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated12 mgoralMylan Institutional Inc.2012-08-31Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated4 mgoralCitron Pharma LLC2011-03-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated8 mgoralCitron Pharma LLC2011-03-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated12 mgoralCitron Pharma LLC2011-03-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated4 mgoralApotex Corp.2012-11-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated8 mgoralApotex Corp.2012-11-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated12 mgoralApotex Corp.2012-11-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated4 mgoralCadila Healthcare Limited2011-10-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated8 mgoralCadila Healthcare Limited2011-10-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated12 mgoralCadila Healthcare Limited2011-10-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated4 mgoralAurobindo Pharma Limited2011-03-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated8 mgoralAurobindo Pharma Limited2011-03-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated12 mgoralAurobindo Pharma Limited2011-03-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated4 mgoralAmerican Health Packaging2014-06-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated4 mgoralZydus Pharmaceuticals (USA) Inc.2011-10-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated8 mgoralZydus Pharmaceuticals (USA) Inc.2011-10-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Galantaminetablet, film coated12 mgoralZydus Pharmaceuticals (USA) Inc.2011-10-10Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
LycoremineNot Available
NivalinNot Available
ReminylNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Galantamine hydrobromide
Thumb
  • InChI Key: QORVDGQLPPAFRS-XPSHAMGMSA-N
  • Monoisotopic Mass: 367.078306222
  • Average Mass: 368.265
DBSALT000316
Categories
CAS number357-70-0
WeightAverage: 287.3535
Monoisotopic: 287.152143543
Chemical FormulaC17H21NO3
InChI KeyASUTZQLVASHGKV-JDFRZJQESA-N
InChI
InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1
IUPAC Name
(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6(17),7,9,15-tetraen-14-ol
SMILES
[H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as galanthamine-type amaryllidaceae alkaloids. These are amaryllidaceae alkaloids with a structure characterized a tetracyclic skeleton with two ortho aromatic protons in ring A.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassAmaryllidaceae alkaloids
Sub ClassGalanthamine-type amaryllidaceae alkaloids
Direct ParentGalanthamine-type amaryllidaceae alkaloids
Alternative Parents
Substituents
  • Galanthamine-type amaryllidaceae alkaloid
  • Benzazepine
  • Benzofuran
  • Anisole
  • Aralkylamine
  • Azepine
  • Alkyl aryl ether
  • Benzenoid
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary alcohol
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of mild to moderate dementia of the Alzheimer's type. Has also been investigated in patients with mild cognitive impairment who did not meet the diagnostic criteria for Alzheimer's disease.
PharmacodynamicsGalantamine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. It is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. An early pathophysiological feature of Alzheimer's disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Galantamine is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, Galantamine's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact. There is no evidence that Galantamine alters the course of the underlying dementing process.
Mechanism of actionGalantamine is a phenanthrene alkaloid and a reversible, competitive acetylcholinesterase inhibitor. It is not structurally related to other acetylcholinesterase inhibitors. Galantamine's proposed mechanism of action involves the reversible inhibition of acetylcholinesterase, which prevents the hydrolysis of acetycholine, leading to an increased concentration of acetylcholine at cholinergic synapses. Galantamine also binds allosterically with nicotinic acetylcholine receptors and may possibly potentiate the action of agonists (such as acetylcholine) at these receptors.
AbsorptionNot Available
Volume of distribution
  • 175 L
Protein binding18%
MetabolismNot Available
Route of eliminationGalantamine is metabolized by hepatic cytochrome P450 enzymes, glucuronidated, and excreted unchanged in the urine.
Half life7 hours
Clearance
  • 300 mL/min [After IV. or oral administration]
ToxicityLD50=75 mg/kg (rat)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9959
Caco-2 permeable+0.8259
P-glycoprotein substrateSubstrate0.8976
P-glycoprotein inhibitor IInhibitor0.6069
P-glycoprotein inhibitor IINon-inhibitor0.9443
Renal organic cation transporterInhibitor0.5728
CYP450 2C9 substrateNon-substrate0.8072
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 substrateNon-inhibitor0.9071
CYP450 2D6 substrateNon-inhibitor0.5414
CYP450 2C19 substrateNon-inhibitor0.8301
CYP450 3A4 substrateNon-inhibitor0.8832
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9439
Ames testNon AMES toxic0.7995
CarcinogenicityNon-carcinogens0.9055
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7790 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8023
hERG inhibition (predictor II)Non-inhibitor0.7424
Pharmacoeconomics
Manufacturers
  • Barr laboratories inc
  • Impax laboratories inc
  • Watson laboratories inc
  • Ortho mcneil janssen pharmaceuticals inc
  • Roxane laboratories inc
  • Ortho mcneil janssen pharmaceutical inc
  • Actavis elizabeth llc
  • Beijing yabao biopharmaceutical co ltd
  • Dr reddys laboratories ltd
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa
Packagers
Dosage forms
FormRouteStrength
Capsule, extended releaseoral16 mg
Capsule, extended releaseoral24 mg
Capsule, extended releaseoral8 mg
Solutionoral4 mg/mL
Tablet, film coatedoral12 mg
Tablet, film coatedoral4 mg
Tablet, film coatedoral8 mg
Prices
Unit descriptionCostUnit
Galantamine Hydrobromide 30 16 mg 24 Hour Capsule Bottle198.58USD bottle
Galantamine Hydrobromide 30 8 mg 24 Hour Capsule Bottle198.58USD bottle
Razadyne 12 mg tablet8.3USD tablet
Razadyne 4 mg tablet5.36USD tablet
Razadyne 8 mg tablet3.66USD tablet
Galantamine hbr 12 mg tablet3.18USD tablet
Galantamine hbr 4 mg tablet3.18USD tablet
Galantamine hbr 8 mg tablet3.18USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
Canada23109262001-11-202017-06-06
Canada23580622006-12-192019-12-20
United States60998631997-06-062017-06-06
United States71605591999-12-202019-12-20
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point269-270 °C (HBr salt)Not Available
water solubility10 mg/mL (HBr salt)Not Available
logP1.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.7 mg/mLALOGPS
logP1.39ALOGPS
logP1.16ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)14.81ChemAxon
pKa (Strongest Basic)8.91ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area41.93 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity82.3 m3·mol-1ChemAxon
Polarizability31.4 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraMS
References
Synthesis Reference

Vijaya Bolugoddu, Sanjay Shukla, Mukunda Jambula, Rajeshwar Sagyam, Ramchandra Pingili, Ananda Thirunavakarasu, “Preparation of (-)-galantamine hydrobromide.” U.S. Patent US20060009640, issued January 12, 2006.

US20060009640
General Reference
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer’s disease. Drugs. 2000 Nov;60(5):1095-122. Pubmed
  2. Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL: Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett. 1999 Dec 17;463(3):321-6. Pubmed
  3. Woodruff-Pak DS, Vogel RW 3rd, Wenk GL: Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):2089-94. Epub 2001 Feb 6. Pubmed
  4. Birks J: Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. Pubmed# Lilienfeld S: Galantamine—a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002 Summer;8(2):159-76. Pubmed
  5. Olin J, Schneider L: Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev. 2002;(3):CD001747. Pubmed# Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer’s disease. Drugs. 2000 Nov;60(5):1095-122. Pubmed
External Links
ATC CodesN06DA04
AHFS Codes
  • 12:04.00
PDB EntriesNot Available
FDA labelDownload (278 KB)
MSDSDownload (28.4 KB)
Interactions
Drug Interactions
Drug
AcepromazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
AcetophenazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
AcetylcholineAcetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists.
AmisulprideAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
AripiprazoleAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
BenzquinamideAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
BretyliumMay enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.
CarbacholAcetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists.
CarphenazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
ChlormezanoneAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
ChlorpromazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
ChlorprothixeneAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
ClozapineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
DipyridamoleMay diminish the therapeutic effect of Acetylcholinesterase Inhibitors.
DroperidolAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
FencamfamineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
FlupentixolAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
FluphenazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
FluspirileneAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
HaloperidolAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
LacosamideBradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide.
LoxapineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
MesoridazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
MethotrimeprazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
MifepristoneMay enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying).
MolindoneAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
OlanzapineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
OndansetronAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
PaliperidoneAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
ParoxetineSelective Serotonin Reuptake Inhibitors may decrease the metabolism of Galantamine.
PerphenazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
PimozideAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
PiperacetazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
ProchlorperazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
PromazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
QuetiapineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
RemoxiprideAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
ReserpineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
RisperidoneAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
RuxolitinibMay enhance the bradycardic effect of Bradycardia-Causing Agents.
SertindoleAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
SertralineSelective Serotonin Reuptake Inhibitors may decrease the metabolism of Galantamine.
SuccinylcholineAcetylcholinesterase Inhibitors may increase the serum concentration of Succinylcholine.
SulpirideAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
ThioridazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
ThiothixeneAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
TofacitinibMay enhance the bradycardic effect of Bradycardia-Causing Agents.
TrifluoperazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
TriflupromazineAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
VilazodoneSelective Serotonin Reuptake Inhibitors may decrease the metabolism of Galantamine.
ZiprasidoneAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
ZuclopenthixolAcetylcholinesterase Inhibitors (Central) may enhance the neurotoxic (central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in some patients.
Food Interactions
  • Take with food.

Targets

1. Acetylcholinesterase

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Acetylcholinesterase P22303 Details

References:

  1. Tonkopii VD, Prozorovskii VB, Suslova IM: [Interaction of reversible inhibitors with the catalytic centers and allosteric sites of cholinesterases] Biull Eksp Biol Med. 1976 Aug;82(8):947-50. Pubmed
  2. Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL: Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett. 1999 Dec 17;463(3):321-6. Pubmed
  3. Guillou C, Mary A, Renko DZ, Gras E, Thal C: Potent acetylcholinesterase inhibitors: design, synthesis and structure-activity relationships of alkylene linked bis-galanthamine and galanthamine-galanthaminium salts. Bioorg Med Chem Lett. 2000 Apr 3;10(7):637-9. Pubmed
  4. Blesa R: Galantamine: therapeutic effects beyond cognition. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:28-34. Pubmed
  5. Stahl SM: The new cholinesterase inhibitors for Alzheimer’s disease, Part 1: their similarities are different. J Clin Psychiatry. 2000 Oct;61(10):710-1. Pubmed
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  7. Lilienfeld S: Galantamine—a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002 Summer;8(2):159-76. Pubmed
  8. Olin J, Schneider L: Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev. 2002;(3):CD001747. Pubmed# Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer’s disease. Drugs. 2000 Nov;60(5):1095-122. Pubmed
  9. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. Pubmed
  10. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. Pubmed
  11. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Pubmed
  12. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. Pubmed

2. Acetylcholine receptor subunit alpha

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: allosteric modulator

Components

Name UniProt ID Details
Acetylcholine receptor subunit alpha P02708 Details

References:

  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer’s disease. Drugs. 2000 Nov;60(5):1095-122. Pubmed
  2. Lilienfeld S: Galantamine—a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002 Summer;8(2):159-76. Pubmed
  3. Olin J, Schneider L: Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev. 2002;(3):CD001747. Pubmed
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. Pubmed
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. Pubmed
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Pubmed

3. Acetylcholine receptor subunit beta

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: allosteric modulator

Components

Name UniProt ID Details
Acetylcholine receptor subunit beta P11230 Details

References:

  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer’s disease. Drugs. 2000 Nov;60(5):1095-122. Pubmed
  2. Lilienfeld S: Galantamine—a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002 Summer;8(2):159-76. Pubmed
  3. Olin J, Schneider L: Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev. 2002;(3):CD001747. Pubmed
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. Pubmed
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. Pubmed
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Pubmed

4. Acetylcholine receptor subunit delta

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: allosteric modulator

Components

Name UniProt ID Details
Acetylcholine receptor subunit delta Q07001 Details

References:

  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer’s disease. Drugs. 2000 Nov;60(5):1095-122. Pubmed
  2. Lilienfeld S: Galantamine—a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002 Summer;8(2):159-76. Pubmed
  3. Olin J, Schneider L: Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev. 2002;(3):CD001747. Pubmed
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. Pubmed
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. Pubmed
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Pubmed

5. Acetylcholine receptor subunit gamma

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: allosteric modulator

Components

Name UniProt ID Details
Acetylcholine receptor subunit gamma P07510 Details

References:

  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer’s disease. Drugs. 2000 Nov;60(5):1095-122. Pubmed
  2. Lilienfeld S: Galantamine—a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002 Summer;8(2):159-76. Pubmed
  3. Olin J, Schneider L: Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev. 2002;(3):CD001747. Pubmed
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. Pubmed
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. Pubmed
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Pubmed

6. Acetylcholine receptor subunit epsilon

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: allosteric modulator

Components

Name UniProt ID Details
Acetylcholine receptor subunit epsilon Q04844 Details

References:

  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer’s disease. Drugs. 2000 Nov;60(5):1095-122. Pubmed
  2. Lilienfeld S: Galantamine—a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002 Summer;8(2):159-76. Pubmed
  3. Olin J, Schneider L: Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev. 2002;(3):CD001747. Pubmed
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. Pubmed
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. Pubmed
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Pubmed

7. Neuronal acetylcholine receptor subunit alpha-2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: allosteric modulator

Components

Name UniProt ID Details
Neuronal acetylcholine receptor subunit alpha-2 Q15822 Details

References:

  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer’s disease. Drugs. 2000 Nov;60(5):1095-122. Pubmed
  2. Lilienfeld S: Galantamine—a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002 Summer;8(2):159-76. Pubmed
  3. Olin J, Schneider L: Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev. 2002;(3):CD001747. Pubmed
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. Pubmed
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. Pubmed
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Pubmed

8. Neuronal acetylcholine receptor subunit alpha-3

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: allosteric modulator

Components

Name UniProt ID Details
Neuronal acetylcholine receptor subunit alpha-3 P32297 Details

References:

  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer’s disease. Drugs. 2000 Nov;60(5):1095-122. Pubmed
  2. Lilienfeld S: Galantamine—a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002 Summer;8(2):159-76. Pubmed
  3. Olin J, Schneider L: Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev. 2002;(3):CD001747. Pubmed
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. Pubmed
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. Pubmed
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Pubmed

9. Neuronal acetylcholine receptor subunit alpha-4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: allosteric modulator

Components

Name UniProt ID Details
Neuronal acetylcholine receptor subunit alpha-4 P43681 Details

References:

  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer’s disease. Drugs. 2000 Nov;60(5):1095-122. Pubmed
  2. Lilienfeld S: Galantamine—a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002 Summer;8(2):159-76. Pubmed
  3. Olin J, Schneider L: Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev. 2002;(3):CD001747. Pubmed
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. Pubmed
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. Pubmed
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Pubmed

10. Neuronal acetylcholine receptor subunit alpha-5

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: allosteric modulator

Components

Name UniProt ID Details
Neuronal acetylcholine receptor subunit alpha-5 P30532 Details

References:

  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer’s disease. Drugs. 2000 Nov;60(5):1095-122. Pubmed
  2. Lilienfeld S: Galantamine—a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002 Summer;8(2):159-76. Pubmed
  3. Olin J, Schneider L: Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev. 2002;(3):CD001747. Pubmed
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. Pubmed
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. Pubmed
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Pubmed

11. Neuronal acetylcholine receptor subunit alpha-6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: allosteric modulator

Components

Name UniProt ID Details
Neuronal acetylcholine receptor subunit alpha-6 Q15825 Details

References:

  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer’s disease. Drugs. 2000 Nov;60(5):1095-122. Pubmed
  2. Lilienfeld S: Galantamine—a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002 Summer;8(2):159-76. Pubmed
  3. Olin J, Schneider L: Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev. 2002;(3):CD001747. Pubmed
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. Pubmed
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. Pubmed
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Pubmed

12. Neuronal acetylcholine receptor subunit alpha-7

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: allosteric modulator

Components

Name UniProt ID Details
Neuronal acetylcholine receptor subunit alpha-7 P36544 Details

References:

  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer’s disease. Drugs. 2000 Nov;60(5):1095-122. Pubmed
  2. Lilienfeld S: Galantamine—a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002 Summer;8(2):159-76. Pubmed
  3. Olin J, Schneider L: Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev. 2002;(3):CD001747. Pubmed
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. Pubmed
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. Pubmed
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Pubmed

13. Neuronal acetylcholine receptor subunit alpha-9

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: allosteric modulator

Components

Name UniProt ID Details
Neuronal acetylcholine receptor subunit alpha-9 Q9UGM1 Details

References:

  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer’s disease. Drugs. 2000 Nov;60(5):1095-122. Pubmed
  2. Lilienfeld S: Galantamine—a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002 Summer;8(2):159-76. Pubmed
  3. Olin J, Schneider L: Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev. 2002;(3):CD001747. Pubmed
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. Pubmed
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. Pubmed
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Pubmed

14. Neuronal acetylcholine receptor subunit alpha-10

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: allosteric modulator

Components

Name UniProt ID Details
Neuronal acetylcholine receptor subunit alpha-10 Q9GZZ6 Details

References:

  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer’s disease. Drugs. 2000 Nov;60(5):1095-122. Pubmed
  2. Lilienfeld S: Galantamine—a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002 Summer;8(2):159-76. Pubmed
  3. Olin J, Schneider L: Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev. 2002;(3):CD001747. Pubmed
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. Pubmed
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. Pubmed
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Pubmed

15. Neuronal acetylcholine receptor subunit beta-2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: allosteric modulator

Components

Name UniProt ID Details
Neuronal acetylcholine receptor subunit beta-2 P17787 Details

References:

  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer’s disease. Drugs. 2000 Nov;60(5):1095-122. Pubmed
  2. Lilienfeld S: Galantamine—a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002 Summer;8(2):159-76. Pubmed
  3. Olin J, Schneider L: Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev. 2002;(3):CD001747. Pubmed
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. Pubmed
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. Pubmed
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Pubmed

16. Neuronal acetylcholine receptor subunit beta-3

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: allosteric modulator

Components

Name UniProt ID Details
Neuronal acetylcholine receptor subunit beta-3 Q05901 Details

References:

  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer’s disease. Drugs. 2000 Nov;60(5):1095-122. Pubmed
  2. Lilienfeld S: Galantamine—a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002 Summer;8(2):159-76. Pubmed
  3. Olin J, Schneider L: Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev. 2002;(3):CD001747. Pubmed
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. Pubmed
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. Pubmed
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Pubmed

17. Neuronal acetylcholine receptor subunit beta-4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: allosteric modulator

Components

Name UniProt ID Details
Neuronal acetylcholine receptor subunit beta-4 P30926 Details

References:

  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer’s disease. Drugs. 2000 Nov;60(5):1095-122. Pubmed
  2. Lilienfeld S: Galantamine—a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002 Summer;8(2):159-76. Pubmed
  3. Olin J, Schneider L: Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev. 2002;(3):CD001747. Pubmed
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. Pubmed
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. Pubmed
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Pubmed

18. Cholinesterase

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cholinesterase P06276 Details

References:

  1. Svoboda Z, Kvetina J, Kunesova G, Herink J, Bajgar J, Bartosova L, Zivny P, Palicka V: Effect of galantamine on acetylcholinesterase and butyrylcholinesterase activities in the presence of L-carnitine in rat selected brain and peripheral tissues. Neuro Endocrinol Lett. 2006 Dec;27 Suppl 2:183-6. Pubmed
  2. Giacobini E: Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer’s disease? Drugs Aging. 2001;18(12):891-8. Pubmed
  3. Wilkinson DG: Galantamine: a new treatment for Alzheimer’s disease. Expert Rev Neurother. 2001 Nov;1(2):153-9. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 2D6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:11